在一线卵巢癌治疗中优化bevacizumab剂量:PGOG-ov1试验
Marta Ostrowska-Leśko1, Radosław Mądry2, Marcin Bobiński3
1Independent Laboratory of Translational Medicine, Chair of Medical Genetics, Medical University of Lublin, Lublin, Poland. marta.ostrowska-lesko@umlub.pl.
Trials
|September 2, 2025
概括
这项研究比较了两种贝瓦西祖马布治疗晚期卵巢癌的剂量,评估了BRCA突变或HRD患者的疗效,安全性和成本效益. 这些发现旨在优化治疗方案,以获得更好的患者结果.
科学领域:
- 癌症学
- 临床药理学
- 基因组学
背景情况:
- 贝瓦西祖马布可以改善晚期卵巢癌的结果.
- 最佳剂量 (7. 5毫克/ 千克对15毫克/ 千克) 和对患者子组的影响 (BRCA突变,HRD) 需要进一步研究.
研究的目的:
- 在晚期卵巢癌中比较7. 5 mg/ kg和15 mg/ kg贝瓦西祖马布的疗效,安全性和成本效益.
- 根据BRCA突变状态和同源重组缺陷 (HRD) 分析治疗结果.
主要方法:
- 在新诊断的晚期 (FIGO III/ IV) 卵巢,输卵管或初级腹腔癌中进行多中心随机临床试验.
- 新辅助化疗使用贝瓦西祖马布,间隔除手术,其次是辅助贝瓦西祖马布 (7. 5 mg/ kg 或 15 mg/ kg) 配合或不配合olaparib.
- 根据BRCA和HRD状态进行分层;主要终点是无进展生存率.
主要成果:
- 主要终点:没有进展的生存率.
- 二级终点:整体反应率,生活质量,安全性.
- 小组分析将评估BRCA和HRD状态对结果的影响.
结论:
- 这项试验将提供关于晚期卵巢癌中贝瓦西祖马布剂量策略的关键数据.
- 这些发现可能会导致更具成本效益和更安全的治疗方案,而不会影响疗效.
- 考虑患者特异性基因组特征 (BRCA/ HRD) 的贝瓦西祖马布治疗优化.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Cancer Survival Analysis
448
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
448
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Drug Dosage Regimen: Overview
3.8K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.8K


